Implications of Postprandial Hyperglycaemia and Role of Voglibose in Type 2 Diabetes Mellitus

Pattanaik, Smita; Baker, Abu; Sinha, Nirmal K.; Kumar, Neeraj; Swami, Onkar C

doi:10.7860/jcdr/2018/32803.11399

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariate regression analysis revealed that postprandial hyperglycemia was associated with 2.4 times higher risk of nephropathy and 79% increased risk of neuropathy [18]. Studies have revealed a consistent and significant correlation between postprandial hyperglycemia and the risk of CVD events and mortality [17,[19][20][21][22][23]41]. Moreover, the risk of CVD and associated mortality is higher in Indians and Asian Indians compared to other populations [42][43][44][45].…”

Section: Optimum Control Of Postprandial Hyperglycemiamentioning

confidence: 99%

“…Moreover, the risk of CVD and associated mortality is higher in Indians and Asian Indians compared to other populations [42][43][44][45]. Some of the pathophysiological mechanisms explaining the correlation between increased PPG and CVD risk include production of free radicals, increase in oxidative stress, endothelial function disorder, low-grade inflammation, blood coagulation, reduction in fibrinolysis and early-phase insulin secretion, and increased insulin resistance [21,23].…”

Section: Optimum Control Of Postprandial Hyperglycemiamentioning

confidence: 99%

“…PPG has been shown to be an important predictor of micro-and macrovascular complications and mortality in individuals with T2DM [16][17][18]. Epidemiological studies around the globe have further provided qualitative evidence on the correlation of increased PPG and CVD [19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus

et al. 2021

View full text Add to dashboard Cite

Evidence suggests a major contribution of postprandial glucose (PPG) excursions to the increased risk of micro- and macro-vascular complications in individuals with type 2 diabetes mellitus (T2DM). Administration of bolus insulin remains a very effective therapeutic option for PPG control. The aim of this expert group recommendation document was to provide practical and easy-to-execute guidelines for physicians on the appropriate use of bolus insulin in the management of T2DM. A panel of key opinion leaders from India reviewed and discussed the available clinical evidence and guideline recommendations on the following topics: (1) optimum control of PPG; (2) choice of bolus insulin; and (3) special situations and practical considerations. The expert panel critically analyzed the current literature and clinical practice guidelines and factored their rich clinical experience to develop a set of nine expert group recommendations for the effective use of bolus insulin. These recommendations will not only result in a more evidence-based application of bolus insulin in the clinical setting but also trigger further research and provide a valuable base for the development of future guidelines on the use of bolus insulin in the management of individuals with T2DM.

show abstract

Section: Optimum Control Of Postprandial Hyperglycemiamentioning

confidence: 99%

Section: Optimum Control Of Postprandial Hyperglycemiamentioning

confidence: 99%

See 1 more Smart Citation

Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is a chronic metabolic disorder characterized by high plasma glucose levels as a result of deficiency in the release of insulin, insulin action or both. 2 Currently, 537 million people worldwide are affected by diabetes, and this figure is expected to elevate to 643 million by 2030, then by 2045 would have increased to 783 million. 3 The classification of diabetes can be in three types depending on the way it develops: type 1 diabetes (T1D), type 2 diabetes (T2DM) and gestational diabetes.…”

Section: Introductionmentioning

confidence: 99%

Effects of Selected Terminalia and Ficus Species in the Inhibition of α-Amylase and α- Glucosidase Enzymes

2023

TJNPR

View full text Add to dashboard Cite

Some Ficus and Terminalia species are relevant in the management of diabetes mellitus but their antidiabetic principles and mechanism of action are yet to be investigated. This study was aimed at investigating the inhibitory potential of ten ethnobotanically selected Ficus and Terminalia species against α-amylase and α-glucosidase enzymes. The methanol extracts of ten selected plants from Ficus and Terminalia genera were tested for their inhibitory activity against porcine pancreatic α-amylase and α-glucosidase from Saccharomyces cerevisiae using colorimetric assay. Acarbose was used as the standard. Percentage inhibition was determined and IC50 value was calculated by analyzing dose-response data using non-linear regression with the aid of GraphPad prism® (7). The result showed that six plant extracts inhibited α-amylase enzyme while all the ten extracts displayed inhibition against glucosidase enzyme in a concentration-dependent manner. Terminalia mollis, F. capensis, and F. vogelli leaf extracts showed significant (p<0.05) inhibitory activity on α-amylase enzyme with IC50 of 344.47±4.66, 343.73±6.13; and 1630.67±2.85 µg/mL, respectively, compared to other extracts. A significant inhibitory activity of these extracts was also observed against α-glucosidase enzyme with IC50 of 6.482±0.61, 11.36±1.01, and 78.47±1.94 µg/mL, respectively, compared to acarbose IC50 2584±9.61 µg/mL. The results from this investigation justify the folkloric usage of these plants for the management of diabetes mellitus. Hence, further investigation is ongoing to isolate and characterize the antidiabetic principles from T. mollis, and F. capensis methanolic leaf extracts.

show abstract

“…[16][17][18][19][20] Voglibose, a potent competitive inhibitor of intestinal α-glucosidase, delays digestion and absorption of dietary polysaccharides, resulting in effective control of PPG excursions, HbA1c levels, and weight gain. [21][22][23][24][25] Usually, voglibose is administered as 0.2 mg thrice daily before each meal, but the dosage can be increased to 0.3 mg in cases of aggravated PPG response. 22,26 Voglibose has been considered safe (due to poor absorption after oral use) and effective as a monotherapy or a combination therapy.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose

Kasthuri

Poongothai

Anjana

et al. 2021

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Purpose: To determine the effect of Voglibose add-on therapy on daily glycemic excursions (using FreeStyle ® Libre Pro™, a Flash glucose monitoring system) in Indian patients with type 2 diabetes (T2DM) receiving a stable dose of metformin (Met) or metformin+sulfonylurea (Met+SU). Patients and Methods: T2DM patients with glycosylated hemoglobin (HbA1c) >7.0% and at least two postprandial excursions > 140 mg/dL (within 2 hours of meal) during the screening phase (visit 1/day-14±2), were enrolled in this prospective, multi-centre interventional study. The patients were randomized at visit 2 (Day 0±2) to receive Voglibose 0.2 mg or 0.3 mg tablets (BID/TID) as add-on therapy to Met and Met+SU. All

show abstract

Implications of Postprandial Hyperglycaemia and Role of Voglibose in Type 2 Diabetes Mellitus

Cited by 6 publications

References 0 publications

Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus

Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus

Effects of Selected Terminalia and Ficus Species in the Inhibition of α-Amylase and α- Glucosidase Enzymes

Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose

Contact Info

Product

Resources

About